Celebrating Success: RA Case Study First Participants In!

21-9

Bildtext

The PREFER rheumatoid arthritis case study team are celebrating the successful start of recruitment and data collection. The first focus group to inform the development of a treatment choice survey was conducted on Wednesday 29th May 2019 with seven members of the public in Birmingham, UK. A second focus group is scheduled to follow a week later, followed by more focus groups with relatives of patients with rheumatoid arthritis.

This exciting and important milestone marks the beginning of our study to identify and assess the attributes that matter to people when making decisions about preventive treatments for rheumatoid arthritis. The content of the focus groups has been designed in collaboration with a team of patient research partners, who will also help to validate the findings of the focus groups and develop a choice survey based on the findings. The survey will also address methodological research questions to inform PREFER recommendations on how and when patient preferences should be integrated into drug development.

By Rachael DiSantostefano

YouTube

About PREFER case studies (Link removed)

CONTACT US

X: @IMI_PREFER

LinkedIn

YouTube

  •  
  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.
  •  

PREFER

The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).